I think it's important to remember that the data was still blinded - even the FDA couldn't see the data on 10/12. This line of reasoning is off base at face value.
Now, why the FDA required additional patients is still an interesting question. I have a completely unsubstantiated theory based on the rejected ODD application, but it has nothing to do with data.